03:40 PM EST - Transition Therapeutics Inc. : announced the results of a five-week proof of concept clinical study of TT-401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT-401 a once-weekly administered peptide, demonstrated significant improvements in glycemic control and reductions in body weight. Transition Therapeutics Inc.
shares T.TTH are trading up $0.95 at $3.20.
